PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details​​​​​​.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

USO 22331

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

 

Disease Types: Leukemia & Lymphoma Research

Eligibility Requirements:

- Diagnosis of chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) as per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 diagnostic criteria

- For ibruinib + venetocIax (I+V) cohorts: eastern cooperative oncology group (ECOG) performance status of 0-1. For ibrutinib monotherapy cohorts: ECOG performance status of 0-2

- Measurable nodal disease by computed tomography (CT), defined as at least 1 lymph node greater than and equal to (>=) 1.5 centimeters (cm) in longest diameter

- A participant using oral contraceptives must use an additional contraceptive method

- A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study treatment

Available at: